The Patent Finder

Immunoforge Co., Ltd.

12 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Aug 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 19, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,700,598Modified Vasoactive Intestinal Peptides
In force
 · High confidence
In forceHigh confidence
US 10,940,182Use of Modified Vasoactive Intestinal Peptides in the Treatment of Hypertension
In force
 · High confidence
In forceHigh confidence
US 9,029,505Modified Vasoactive Intestinal Peptides
In force
 · High confidence
In forceHigh confidence
US 9,561,262Use of Modified Vasoactive Intestinal Peptides in the Treatment of Hypertension
In force
 · High confidence
In forceHigh confidence
US 9,919,032A Method for Administering a Sustained Release Formulation
In force
 · High confidence
In forceHigh confidence
US 11,052,132Methods and Compositions for Treating Cystic Fibrosis
In force
 · High confidence
In forceHigh confidence
US 10,722,590Elp Fusion Proteins for Controlled and Sustained Release
In force
 · High confidence
In forceHigh confidence
US 10,688,156Methods and Compositions for Treating Muscle Disease and Disorders
In force
 · High confidence
In forceHigh confidence
US 11,266,719Methods and Compositions for Treating Muscle Disease and Disorders
In force
 · High confidence
In forceHigh confidence
US 10,993,993Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist
In force
 · USPTO record
In forceUSPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 2 abandoned · 1 no status recorded

Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/022,662Jan 15, 2025Pending
19/001,138Modified Vasoactive Intestinal PeptidesDec 24, 2024Pending
18/984,814Dec 17, 2024Pending
18/421,886Elp Fusion Proteins for Controlled and Sustained ReleaseJan 24, 2024Pending
18/323,208May 24, 2023Abandoned
18/862,754May 4, 2023No status recorded
18/311,049May 2, 2023Abandoned
18/265,079Fusion Protein Including GLP-1 Receptor Agonist, and Anti-Oscar Antibody and Use ThereofJul 29, 2021Pending
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited